BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wiegand T, Mcvey A, Nemudraia A, Nemudryi A, Wiedenheft B. The rise and fall of SARS-CoV-2 variants and the emergence of competing Omicron lineages.. [DOI: 10.1101/2022.02.09.479842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Pedenko B, Sulbaran G, Guilligay D, Effantin G, Weissenhorn W. SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses 2023;15. [PMID: 36851772 DOI: 10.3390/v15020558] [Reference Citation Analysis]
2 Rahman MM, Estifanos B, Glenn HL, Kibler K, Li Y, Jacobs B, McFadden G, Hogue BG. Nuclear export inhibitor Selinexor targeting XPO1 enhances coronavirus replication. bioRxiv 2023:2023. [PMID: 36824761 DOI: 10.1101/2023.02.09.527884] [Reference Citation Analysis]
3 Shi D, Bu C, He P, Song Y, Dordick JS, Linhardt RJ, Chi L, Zhang F. Structural Characteristics of Heparin Binding to SARS-CoV-2 Spike Protein RBD of Omicron Sub-Lineages BA.2.12.1, BA.4 and BA.5. Viruses 2022;14. [PMID: 36560700 DOI: 10.3390/v14122696] [Reference Citation Analysis]
4 Roohani J, Keikha M. Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned? World J Virol 2022; 11(6): 496-501 [DOI: 10.5501/wjv.v11.i6.496] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li Q, Zhang M, Liang Z, Zhang L, Wu X, Yang C, An Y, Tong J, Liu S, Li T, Cui Q, Nie J, Wu J, Huang W, Wang Y. Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD. MedComm 2022;3. [DOI: 10.1002/mco2.130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]